Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Approvals & launches

NeOnc books January FDA session to test faster route for nasal brain cancer drug

Nasdaq-listed NeOnc will ask US regulators in early 2027 whether intranasal NEO100 can be approved on an accelerated basis, with Phase 3 trial design also up for discussion.

18 Nov 2026 · Neonc Technologies Holdings, Inc. NTHI · Company news

NeOnc Technologies (Nasdaq: NTHI) has secured a formal slot with the US Food and Drug Administration in early January 2027 to discuss whether its intranasal brain cancer candidate, NEO100, could reach the market through accelerated approval. The company announced the meeting on 16 November.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Neonc Technologies Holdings, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Approvals & launchesAll →